VivoSeq
Nephrology

Peritoneal Dialysis

0

Pipeline Programs↗

11

Active Trials↗

6

Companies Involved↗

Peritoneal Dialysis is an early-stage landscape with 0 programs across 6 companies. The most active players are Iperboreal Pharma Srl, Roche, Bayer.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

84/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Iperboreal Pharma Srl

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalF

Fresenius Medical Care Deutschland GmbH

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

79

clinical trials

Completed43 · 54%
Unknown status17 · 22%
Recruiting8 · 10%
Terminated6 · 8%
Withdrawn2 · 3%
Not yet recruiting2 · 3%
Other1 · 1%

Clinical Trials

Trial Activity

79 trials

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
Recruiting·UUniversity Health Network, Toronto·Phase 3·NCT05715814·20 enrolled
Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients
Recruiting·VVantive Health LLC·N/A·NCT06492031·889 enrolled
Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis Patients
Recruiting·—·Phase 4·NCT07271420·40 enrolled
Pharmacokinetics of Apixaban in Peritoneal Dialysis
Recruiting·—·N/A·NCT05532878·50 enrolled
Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients
Recruiting·SSichuan Academy of Medical Sciences·N/A·NCT06398977·70 enrolled
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
Recruiting·Oman Ministry of Health·N/A·NCT07491042·38 enrolled
Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study
Recruiting·HHull University Teaching Hospitals NHS Trust·Phase 3·NCT06884280·30 enrolled
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
Recruiting·IIperboreal Pharma Srl·Phase 3·NCT03994471·170 enrolled
Hydrocolloid Dressing for Catheter Exit Site Care in Peritoneal Dialysis Patients
Active, not recruiting·SSingapore General Hospital·N/A·NCT05143164·60 enrolled
Amino Acid (15) Peritoneal Dialysis Solution for Nutritional Improvement in Peritoneal Dialysis Patients
Not yet recruiting·SShanghai 10th People's Hospital·Phase 4·NCT07370441·50 enrolled
Development and Validation of a Prediction Model for Peritoneal Kt/Vurea Using Single-Exchange Dialysate Effluent in Patients Undergoing Peritoneal Dialysis
Not yet recruiting·PPeking University First Hospital·N/A·NCT07659067·300 enrolled
A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)
Completed·Roche logoRoche·Phase 1·NCT02617784·24 enrolled
Administration of pH-Neutral Peritoneal Dialysis Solutions Containing Lactate or Bicarbonate in Children
Completed·HHeidelberg University·Phase 4·NCT01632046·42 enrolled
L-Carnitine in Peritoneal Dialysis
Completed·IIperboreal Pharma Srl·Phase 2·NCT00922701·4 enrolled
Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients
Completed·TThe University of Hong Kong·Phase 4·NCT01447368·67 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)